O
Omnio
Sweden · Biotech
Omnio develops a plasminogen-based biologic for chronic wounds, initially diabetic foot ulcers.
Product
Omnio is a Swedish biotechnology company developing a plasminogen-based therapy for chronic wounds. Its initial focus is diabetic foot ulcers, building on research at Umeå University.
The company is preparing manufacturing and toxicology work ahead of clinical trial applications, with an initial Phase I/IIa study targeted for 2027.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Funding round | €2.9M | Participants not disclosed | |
| Funding round | ~€4.3M | Participants not disclosed |